RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Rating) CFO Rodney Kb Young acquired 5,000 shares of the stock in a transaction on Tuesday, May 10th. The stock was bought at an average cost of $10.53 per share, for a total transaction of $52,650.00. Following the transaction, the chief financial officer now owns 10,084 shares of the company’s stock, valued at approximately $106,184.52. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.
Shares of NASDAQ RAPT opened at $12.16 on Friday. RAPT Therapeutics, Inc. has a 1 year low of $9.85 and a 1 year high of $43.26. The firm has a 50-day moving average of $19.81 and a 200 day moving average of $26.19.
RAPT Therapeutics (NASDAQ:RAPT – Get Rating) last issued its earnings results on Wednesday, May 11th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.01). RAPT Therapeutics had a negative return on equity of 39.69% and a negative net margin of 1,814.95%. As a group, research analysts forecast that RAPT Therapeutics, Inc. will post -3.04 earnings per share for the current fiscal year.
Several brokerages have commented on RAPT. Zacks Investment Research lowered shares of RAPT Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, January 20th. Piper Sandler lowered their price objective on shares of RAPT Therapeutics from $52.00 to $30.00 in a research report on Thursday. Wells Fargo & Company lowered their price objective on shares of RAPT Therapeutics from $65.00 to $55.00 and set an “overweight” rating on the stock in a research report on Friday, March 11th. HC Wainwright reiterated a “buy” rating and issued a $56.00 target price on shares of RAPT Therapeutics in a research note on Monday, March 14th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of RAPT Therapeutics in a research note on Friday, April 1st. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $52.25.
RAPT Therapeutics Company Profile (Get Rating)
RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
- Get a free copy of the StockNews.com research report on RAPT Therapeutics (RAPT)
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.